Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerecor gets rights to early-stage epilepsy project from Lilly

Executive Summary

Eli Lilly & Co. granted Cerecor Inc. exclusive global rights to develop and sell LY3130418, a preclinical Transmembrane AMPA Receptor Regulatory Proteins (TARP)-y8-dependent AMPA receptor antagonist for epilepsy.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Reverse Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register